AGIO:NSD-Agios Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 52.90

Change

0.00 (0.00)%

Market Cap

USD 3.64B

Volume

0.30M

Average Target Price

USD 70.75 (+33.74%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD76.34B 51.29 38.52
REGN Regeneron Pharmaceuticals, Inc

N/A

USD63.70B 32.18 22.32
SGEN Seattle Genetics, Inc

N/A

USD30.18B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD24.03B 10.20 8.76
MRNA Moderna, Inc

N/A

USD23.24B N/A N/A
GMAB Genmab A/S

N/A

USD22.91B 49.21 4.63
BMRN BioMarin Pharmaceutical Inc

N/A

USD22.80B 201.29 120.75
INCY Incyte Corporation

N/A

USD22.77B 47.64 35.20
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD18.63B N/A N/A
BGNE BeiGene, Ltd

N/A

USD15.57B N/A N/A

ETFs Containing AGIO

Symbol Name Weight Mer Price(Change) Market Cap
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

USD0.10B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.04 %

N/A

USD0.39B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.21B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.79% 58% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.79% 58% F 73% C
Trailing 12 Months  
Capital Gain 17.04% 56% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.04% 56% F 73% C
Trailing 5 Years  
Capital Gain -51.83% 47% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.83% 46% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 0.26% 47% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.26% 47% F 25% F
Risk Return Profile  
Volatility (Standard Deviation) 39.85% 49% F 25% F
Risk Adjusted Return 0.65% 49% F 28% F
Market Capitalization 3.64B 90% A- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.19 43% F 26% F
Price / Cash Flow Ratio -9.83 66% D 81% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -57.59% 58% F 22% F
Return on Invested Capital -64.20% 49% F 15% F
Return on Assets -28.67% 51% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.07 12% F 6% F
Short Percent 16.89% 12% F 13% F
Beta 2.13 24% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector